ArticleJournal of dental sciences2025
Development of zinc partially-stabilized cement carrying growth factor and anti-inflammatory drug for vital pulp therapy.
Article in Journal of dental sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Mineral trioxide aggregate (MTA) is recognized as the gold standard for vital pulp therapy. However, its clinical utility is limited by prolonged setting and poor handling characteristics. To overcome these drawbacks, the zinc-containing partially-stabilized cement (ZnPSC), a modified silicate cement, was developed. In this study, the ZnPSC was functionalized with vascular endothelial growth factor (VEGF) and aspirin to enhance its potential as an effective pulp capping material. Materials and methods: The ZnPSC cements (5 %,7 %, or 10 % of Zn) were combined with poly-γ-glutamic acid (γ-PGA) 1 % or 2 % as a carrier system for VEGF and aspirin. The modified materials were evaluated for the setting time, compressive strength, biocompatibility, controlled drug release, and their ability to promote osteogenic differentiation of dental pulp stem cells (DPSC), assessed by alkaline phosphatase activity and calcium deposition staining. Results: Incorporation of 1 % or 2 % γ-PGA into 5 % or 7 % ZnPSC cements significantly reduced the setting time and enhanced the compressive strength, overcoming the drawbacks associated with MTA and improving clinical workability. The modified materials exhibited excellent biocompatibility without cytotoxic effects. Furthermore, the sustained delivery of VEGF and aspirin markedly enhanced the mineralization and osteogenic differentiation of DPSCs, as evidenced by increased ALP activity and calcium deposition. Conclusion: The novel ZnPSC cements functionalized with VEGF and aspirin demonstrated the superior handling properties, mechanical strength, biocompatibility, and enhanced regenerative potential, making it a promising candidate for the vital pulp therapy. Further, in vivo studies are warranted to validate its therapeutic efficacy and biosafety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.